Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
28 Setembro 2023 - 7:00AM
Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq:
TSBX), a clinical-stage biotechnology company developing new
medicines to treat and cure solid tumors by pioneering a
differentiated approach to tumor-infiltrating lymphocyte (TIL)
therapy, today announced four posters reporting preclinical data
for Turnstone’s Selected TIL therapies will be presented at the
38th Annual Meeting of the Society for Immunotherapy of Cancer
(SITC). The SITC 38th Annual Meeting will be held from November
1-5, 2023, in San Diego, California.
The details of the posters are as follows:
In collaboration with Moffitt Cancer Center
Title |
Expansion and Identification of Neoantigen-Reactive
Tumor-Infiltrating Lymphocytes (TIL) from Metastatic Colorectal
(CRC) and GI Cancers |
Authors |
Matthew Beatty, Madeline
Rodriguez-Valentin, MacLean Hall, Fatema Khambati, Amy Hall,
Larissa Pikor, Timothy Langer, Barbara Sennino, Jamie Teer, Jason
Fleming, Shari Pilon-Thomas |
Presentation
Type |
Poster |
Session Date and
Time |
November 4, 2023: 9:00 AM - 8:30
PM PT |
Abstract
Number |
346 |
Title |
Enhancing Directly Selected Tumor-Reactive TIL Function
Through Genetic Modification |
Authors |
Emily Carron, Sowbarnika Ratliff,
April Fraley, Justin Rahman, Niloufar Khojandi, Bryant Thompson,
Mathew Thayer, Christophe Pedros, Larissa Pikor, Barbara
Sennino |
Presentation
Type |
Poster |
Session Date and
Time |
November 4, 2023: 9:00 AM - 8:30
PM PT |
Abstract
Number |
350 |
In collaboration with Illumina, Inc.
Title |
Tumor Neoantigen Prioritization from Liquid Biopsy Whole
Exome Sequencing for Selected Tumor-Infiltrating Lymphocyte
Therapy |
Authors |
Urminder Singh, Christian Laing,
Jacob Gibson, Anna Kluew, Mahdi Golkaram, Sven Bilke, Larissa
Pikor, Nathalie Brassard, Matthew Beatty, Doris Wiener, Brian
Czerniecki, Shari Pilon-Thomas, Simon Turcotte, Li Liu, Stewart
Abbot, Timothy Langer, Grace DeSantis, Michael Ciancanelli, Jeff
Tsai |
Presentation
Type |
Poster |
Session Date and
Time |
November 4, 2023: 9:00 AM - 8:30
PM PT |
Abstract
Number |
178 |
Title |
TBio BFX 4101: A Neoantigen Prioritization Pipeline for
Selected Tumor-Infiltrating Lymphocyte Therapy |
Authors |
Christian Laing, Quanyuan He,
Tony Collins, Meghan Verschoor, Chantal Martin, Stewart Abbot,
Michael Ciancanelli |
Presentation
Type |
Poster |
Session Date and
Time |
November 4, 2023: 9:00 AM - 8:30
PM PT |
Abstract
Number |
900 |
About Turnstone
Turnstone Biologics is a clinical-stage biotechnology company
developing new medicines to treat and cure solid tumors by
pioneering a differentiated approach to TIL therapy. Turnstone’s
innovative TIL therapy is based upon the identification, selection,
and expansion of the most potent tumor-reactive T cells, known as
Selected TILs, and is designed to overcome the limitations of
first-generation bulk TILs that have demonstrated objective
responses only in limited tumor types. Turnstone’s most advanced
program, TIDAL-01, is currently being evaluated in two Phase 1
studies in patients with melanoma, breast cancer and colorectal
cancer, and the Company is also actively advancing its preclinical
pipeline programs including TIDAL-02, its next Selected TIL
program, and its TIDAL-01 and viral immunotherapy combination
program. For additional information about Turnstone, please visit
www.turnstonebio.com, and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on the beliefs and assumptions of our management team, and on
information currently available to such management team. These
forward-looking statements are subject to numerous risks and
uncertainties, many of which are beyond our control. All
statements, other than statements of historical fact, contained in
this press release, including statements regarding future events,
future financial performance, business strategy and plans, and
objectives of ours for future operations, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will” or “would,” or the negative of these terms or
other comparable terminology. Although we do not make
forward-looking statements unless we believe we have a reasonable
basis for doing so, we cannot guarantee their accuracy. These
statements are only predictions and involve known and unknown
risks, uncertainties and other factors, which may cause our actual
results, levels of activity, performance or achievements of and
those of our industry to be materially different from any future
results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. You should not
place undue reliance on any forward-looking statement. These
statements are not guarantees of future performance and undue
reliance should not be placed on them. Such forward-looking
statements necessarily involve known and unknown risks and
uncertainties, which may cause actual performance and financial
results in future periods to differ materially from any projections
of future performance or result expressed or implied by such
forward-looking statements. Although forward-looking statements
contained in this press release are based upon what management of
the Company believes are reasonable assumptions, there can be no
assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements. We undertake
no obligation to update or revise publicly any of the
forward-looking statements after the date hereof to conform the
statements to actual results or changed expectations except as
required by law. The reader is cautioned not to place undue
reliance on forward-looking statements. This press release
discusses product candidates that are under clinical study and
which have not yet been approved for marketing by the U.S. Food and
Drug Administration. No representation is made as to the safety or
effectiveness of these product candidates for the uses for which
they are being studied. Trade names, trademarks and service marks
of other companies appearing in this press release are the property
of their respective owners. Solely for convenience, the trademarks
and tradenames referred to in this press release appear without the
® and ™ symbols, but those references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under
applicable law, our rights, or the right of the applicable licensor
to these trademarks and tradenames. This press release is not an
offer to sell our securities and it is not soliciting offers to buy
securities nor shall there be any sale of our securities in any
jurisdiction where the offer, solicitation or sale is not
permitted.
Contact
Ahmed AneiziInvestor RelationsTurnstone Biologics(347)
897-5988ahmed.aneizi@turnstonebio.com
Turnstone Biologics (NASDAQ:TSBX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Turnstone Biologics (NASDAQ:TSBX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024